Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a clinical diagnosis of stable plaque psoriasis~* Subject has an ODS score for the Treatment Area of 3 or 4 at study start~Exclusion Criteria:~* Subject has spontaneously improving or rapidly deteriorating plaque psoriasis.~* Subject has guttate, pustular, erythrodermic or other non-plaque forms of psoriasis.~* Subject has used any phototherapy, photo-chemotherapy or systemic corticosteroid therapy within 30 days prior to study start~* Subject has used any systemic methotrexate, retinoids, cyclosporine or analogous products within 90 days prior to study start~* Subject has used any systemic biologic therapy for the treatment of psoriasis within 5 half-lives of the biologic prior to study start~* Subject had prolonged exposure to natural or artificial sources of ultraviolet radiation within 30 days prior to study start~* Subject has used topical body (excluding the scalp) psoriasis therapy including coal tar, anthralin, steroids, retinoids, vitamin D analogs (e.g., Dovonex®) within 14 days prior to study start~* Subject has used emollients/moisturizers on areas to be treated within four hours prior to clinical evaluation at study start~* Subject is currently using lithium or Plaquenil (hydroxychloroquine)~* Subject is currently using a beta-blocking medication (e.g., propranolol) or ACE (e.g., lisinopril) inhibitor at a dose that has not been stabilized~* Subject is pregnant, lactating, or is planning to become pregnant during the study~* Subject is currently enrolled in an investigational drug or device study~* Subject has used an investigational drug or investigational device treatment within 30 days prior to study start~* Subject has been previously enrolled in this study and treated with a test article

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 122-0551 (Type: EXPERIMENTAL): None
- Vehicle (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).